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Abstract
The United States is facing a growing epidemic of unchecked and untreated individuals with
prediabetes. While lifestyle interventions have remained the gold standard of treatment, has this
been enough? A literature review was carried out to identify metformin’s role in treatment and
management of prediabetes as well as perceived barriers to its prescribing. A total of 24 articles
met inclusion criteria. Main findings include (a) metformin is effective in reducing the incidence
of diabetes, though not as effective as lifestyle interventions; (b) certain populations did benefit
more from metformin usage then other populations; (c) there was more treatment compliance
with metformin; (d) metformin was shown to be effective in reducing microvascular
complications often associated with diabetes; (e) while metformin was effective in reducing
diabetes incidence, it has no effect on returning prediabetes to normal glucose ranges; (f)
metformin was shown to be safe and tolerable; and (g) even when metformin was shown to be
effective, it was still under prescribed and underutilized due to a knowledge gap and perceived
barriers by primary care providers. These findings have important practice and policy
implications, including increasing patient and provider awareness of prediabetes and its
complications, developing guidelines regarding screening, diagnosing, and
treatment/management of prediabetes, closing the knowledge gap and perceived barriers of
primary care providers, and developing prevention programs that can be widely implemented.
Further research is needed regarding the long-term implications that metformin has regarding
prediabetes treatment and long-term patient outcomes.
Keywords: prediabetes, pre-diabetes, lifestyle modification, medications,
pharmacological intervention, metformin, management, treatment, gestational diabetes, weight
loss, pioglitazone, insulin
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Metformin’s Role in the Prevention of T2DM in Individual’s Diagnosed with Prediabetes:
A Systematic Literature Review
According to the Centers for Disease Control and Prevention (2020), 88 million
American adults have prediabetes, which equivalates to 1 out of 3 adults. Over 80percent of
those 88 million American adults do not know they have it (Centers for Disease Control and
Prevention [CDC], 2020). Prediabetes increases an individual’s risk of developing Type 2
Diabetes Mellitus (T2DM), heart disease, and stroke (CDC, 2020). The following factors place
an individual at an increased risk for prediabetes: overweight, 45 years of age or older, parent or
sibling with T2DM, physically inactive, history of gestational diabetes, and/or polycystic ovary
syndrome (CDC, 2020). Lifestyle changes such as increasing physical activity and dietary
modifications are the first route to preventing prediabetes from escalating into T2DM. What
about the individuals who continue to have high glucose levels? In cases where an individual has
prediabetes and are considered to be at a high risk for T2DM, recent guidelines recommend
considering use of metformin, especially for patients who are under 60 years old, have a body
mass index (BMI) over 35 kg/m2, or have a history of gestational diabetes (JAMA, 2017). The
question remains what role metformin plays in not only treating prediabetes, but in preventing
T2DM or at least slowing the progression. As the 7th leading cause of death in the United States,
diabetes is a major condition seen in clinical practice. Therefore, finding a safe and effective way
to prevent or slow the progression of prediabetes, would be a major game-changer for our
patient's health (ADA, n.d.)! This systematic literature review aims to examine the research
evidence pertaining to the use of metformin in prediabetes for the prevention of T2DM.
Recommendations for clinical practice and future research will be synthesized.
Prediabetes Background
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Prediabetes occurs when serum blood glucose levels are higher than normal, though not
high enough to be diagnosed as diabetes (American Diabetes Association [ADA], n.d.).
Prediabetes can be diagnosed with the same tests for T2DM, with different diagnostic criteria. To
diagnosis prediabetes, an individual has to have one of the following: (a) glycosylated
hemoglobin (A1C) level between 5.7 percent - 6.4 percent; (b) fasting plasma glucose (FPG)
level between 100 mg/dl – 125 mg/dl; or (c) oral glucose tolerance test (OGTT) level between
140 mg/dl – 199 mg/dl (ADA, n.d.).
According to the National Institute of Diabetes and Digestive and Kidney Diseases
(2017), there is an estimated 30.3 million adults in the United States alone who have diabetes
(9.4 percent of the U.S population). Of those 30.3 million adults, 23.1 million have been
diagnosed, while 7.2 million are undiagnosed. The statistics regarding prediabetes are even more
staggering. An estimated 84.1 million adults in the United States have prediabetes. A total of
23.1 million adults ages 65 or older have prediabetes and more men than women have
prediabetes (National Institute of Diabetes and Digestive and Kidney Diseases, 2017). The
combined total of individuals with T2DM and prediabetes, equals 114.4 million adults in the
United States alone, equating to 43.3 percent of the adult population (National Institute of
Diabetes and Kidney Diseases, 2017). In 2017, $327 billion, including $237 billion in direct
medical costs and $90 billion in reduced productivity, was spent due to diagnosed diabetes
(National Institute of Diabetes and Digestive and Kidney Diseases, 2017).
Prediabetes increases an individual’s risk of developing T2DM, heart disease, and stroke
(CDC, 2019). The increased risk for cardiovascular disease in prediabetes is multifactorial, with
etiologies including insulin resistance, hyperglycemia, dyslipidemia, hypertension, systemic
inflammation, and oxidative stress (Hsueh, Orloski, & Wyne, 2010). When prediabetes leads to
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diabetes, it affects the entire body, with individuals often developing major complications such
as nephropathy, retinopathy, and peripheral neuropathy. Researchers suggest that diabetes
doubles the risk of depression, and that risk increases as more diabetes-related health problems
develop (CDC, 2018).
Known risk factors place an individual at an increased risk for prediabetes and T2DM.
Known risk factors include, being overweight, age 45 years or older, first degree relative with
T2DM, member of a high risk population (African American, Hispanic/Latino, American Indian,
Alaska Native, Asian American, Pacific Islander), physical inactivity, history of gestational
diabetes, or giving birth to an infant over 10 pounds, hypertension, low high density lipoprotein
(HDL) cholesterol level, high triglycerides (TG) level, atherosclerotic cardiovascular disease,
conditions associated with insulin resistance (acanthosis nigricans, non-alcoholic steatohepatitis,
polycystic ovarian syndrome), and treatment with atypical antipsychotics or glucocorticoids
(CDC, 2018; National Institute of Diabetes and Digestive and Kidney Diseases, n.d.).
Prediabetes Management and Current Use of Metformin
Currently, screening for prediabetes is vague, often mimicking screenings for T2DM. The
American Academy of Clinical Endocrinologists (AACE) recommends that individuals who
meet any of the clinical risk criteria, noted above, should be screened for prediabetes or T2DM
(AACE, n.d.). If results are normal, repeat testing at least every three years, but if an individual
has two or more risk factors, annual screening should be considered (AACE, n.d.). Primary
treatment goal for prediabetes is to normalize glucose and prevent the progression to diabetes
and microvascular complications (AACE, n.d.). Therapeutic lifestyle management through a
healthy diet, physical activity, and weight loss is the first choice in management for prediabetes.
Therapeutic lifestyle management entails patient self-monitoring, realistic and stepwise goal
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setting, stimulus control, cognitive strategies, social support, and appropriate reinforcement
(AACE, n.d.). Medical nutrition therapy consists of consistency in day-to-day carbohydrate
intake, limitation of sucrose-containing or high-glycemic index foods, adequate protein intake,
and weight management (AACE, n.d.). Physical activity and weight loss entails individuals
being evaluated initially for contraindications and/or limitation to increased physical activity, an
exercise prescription should be developed for each patient based on his or her goals and
limitations, and any new physical activity should be started slowly and built up gradually
(AACE, n.d). In addition to therapeutic lifestyle management there are pharmacological
approaches to glucose management in prediabetes when diet, weight loss, and physical activity
have not been enough. Pharmacological approaches include, acarbose, thiazolidinediones, insulin
glargine, glucagon-like peptide-1 (GLP-1) receptor agonists and metformin. Metformin is
usually the first line option when adding a pharmacological agent as it has been shown to have
beneficial effects on metabolic syndrome components, including mild to moderate weight loss,
lipid profile improvements, and improved fibrinolysis (AACE, n.d.). However, due to
inconsistent and vague guidelines regarding screenings and treatment, metformin has been
considered underutilized and under prescribed. This systematic review delves into the research
regarding metformin’s effectiveness compared to lifestyle modifications, safety, tolerability,
reduction in microvascular complications and understand the barriers to prescribing.
Clinical Question
Based on the above phenomena of interest, the following clinical question was developed
in PICO format to guide a systematic review of the literature: For adults with Prediabetes (P),
does the use of metformin (I) reduce the future risk of developing T2DM Mellitus and vascular
complications (O) when compared to the usual practice of lifestyle modification alone (C)?
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Importance for Primary Care Providers
Nurse practitioners frequently work as primary care providers and will see patients
frequently who have one or more risk factors for prediabetes and T2DM. A lack of adequate
knowledge regarding how to screen, manage and treat prediabetes can contribute to longstanding
future complications for the patient and family as well as unnecessary spending and cost for our
health care system. When prediabetes is left untreated and unchecked, it has the ability to
progress to T2DM, which can lead to microvascular complications such as hypertension,
hyperlipidemia, heart disease, stroke, kidney disease, nerve damage, vision problems (possibly
loss of vision), and amputations (Mayo Clinic, 2020). Lifestyle management (diet, physical
activity and weight loss) is at the core of treatment for prediabetes and T2DM, but what about
individuals where lifestyle management isn’t enough or barriers such as age and other medical
conditions prevent lifestyle management? The AACE guidelines suggest metformin therapy for
prevention of T2DM should be considered in those with prediabetes, especially for those with
BMI over 35 kg/m2, those ages under 60 years, and women with prior gestational diabetes
(AACE, n.d.). Unfortunately, providers are underutilizing metformin as a treatment option for
prediabetes whether that is from a lack of knowledge, inconsistent and vague guidelines, or
doubt regarding metformin effectiveness, efficacy and/or safety is unclear. Nurse Practitioners
and other primary care providers need to bridge the knowledge gap regarding metformin’s use in
treatment and management of prediabetes to provide clear cut guidelines regarding screening,
treatment and management of prediabetes so we can all work to improve the overall health and
well-being of diabetes patients with competence and confidence.
Methods
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A systematic literature review was performed to explore the current literature as it
pertains to the clinical question listed in the previous section. Six databases were chosen to
provide a wide range of sources and information including CINAHL Plus with Full Test
(CINAHL), Academic Search Premier, MEDLINE (PubMed), SAGE Journals, Google Scholar
(GS), and Nursing and Allied Health Database. Table 1 provides rationales for choosing the six
databases, as well as a list of search restrictions and date ranges for each database. The keywords
prediabetes, pre-diabetes, lifestyle modification, medications, pharmacological intervention,
metformin, prediabetes management, pre-diabetes management, prediabetes treatment, prediabetes treatment, gestational diabetes, weight loss, pioglitazone, and insulin were searched
individually and/or in combination with other keywords in all six databases (see Table 2 in
Appendix for specific keyword combination searches). Of note, the terms gestational diabetes,
weight loss, pioglitazone, and insulin were excluded terms, meaning they were used to specify
that the articles were not to include these terms to help narrow down article selection.
The number of articles obtained in every keyword search or combination in each database
were recorded, and searches with 15 or fewer articles were chosen for a review (see Table 2 in
Appendix, articles for further review are bolded and marked with an asterisk). Of the articles that
were chosen for a brief review, if they eluded a relevance to the identified clinical question or
provided important and relevant information to the overall phenomenon these were marked for a
more in-depth review (see Table 2 in Appendix). There were 72 articles identified, after
eliminating duplicate articles, this review yielded 54 articles to be reviewed for inclusion or
exclusion in the literature review. After extensively reviewing all 54 articles for relevance of the
identified clinical question, 25 articles met the inclusion criteria.
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The 25 articles that met inclusion criteria directly addressed (a) the pharmacodynamics of
metformin; (b) whether metformin alone is superior to lifestyle modifications in preventing or
delaying the progression from prediabetes to T2DM; (c) whether metformin combined with
lifestyle modifications is superior to lifestyle modifications alone in preventing or delaying the
progression from prediabetes to T2DM; (d) the safety, tolerability, and cost-effectiveness of
metformin; (e) metformin’s role in the reduction of microvascular complications that often
coincide with T2DM; (f) barriers to screening/diagnosing prediabetes and barriers to prescribing
metformin; and (g) specific population where metformin may reign superior to lifestyle
modification alone. The 29 articles that met exclusion criteria directly addressed (a) lifestyle
modification alone (no inclusion of metformin or pharmacological interventions), (b) an
incorrect target population (i.e., pediatrics and adolescents only), (c) incorrect disease
progression (i.e., volunteers/patients/participants already diagnosed with T2DM), and (d)
language barrier, such as those available only in Spanish (see Table 3 in Appendix for specific
detail regarding the rational for exclusion and inclusion of each article).
The 25 articles chose for the literature review were read in entirety and analyzed for
identification of study purpose, population/size/setting, level of evidence, variables/instruments,
findings, and implications for practice. The Hierarchy of Evidence (Melynk & Fineout-Overholt,
2015) was used to identify the strength of the research evidence according to levels. The highest
level of evidence obtained were two level I studies, which were systematic reviews of metalanalyses or randomized control trials. There were nine level II studies included, which were all
randomized control trials. Two level III articles were identified, one being a retrospective cohort
study and the other an observational study. There were four level IV studies included, with a mix
of cross-sectional analysis and scoping review of literature. Level V had seven articles included,
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all of which were expert opinion (see Table 4 in Appendix for further detail on level of evidence
and data abstraction of included articles).
The search methods used for this systematic literature review included a variety of
databases and wide range of keywords, which yielded a variety of high-level evidence articles
that applied to the clinical question. The search methods yielded a high number of articles which
provided the ability to be detailed in the exclusion/inclusion criteria to obtain the highest quality
and level of evidence data out there for this specific phenomenon. Other databases, such as
Cochrane could have been included and may have provided more systematic reviews. These
methods yielded a strong body of evidence with nearly half of the studies at a level I or II.
Literature Review
Pharmacodynamics of Metformin
Metformin is the world’s most prescribed anti-diabetic drug and is effective in
delaying/preventing T2DM in people at high risk, by lowering body weight, fat mass, and
circulating insulin levels through mechanisms that aren’t completely understood (Coll et al.,
2019). Metformin’s pharmacological mechanisms of action is that it decreases hepatic glucose
production, decreases intestinal absorption of glucose, and improves insulin sensitivity by
increasing peripheral glucose uptake and utilization (FDA, 2006). However, even though these
mechanisms of action of metformin have been identified, they do not sufficiently explain the
beneficial weight loss promoting effects (Coll et al., 2019). Recent studies have seen an
association between metformin and circulating levels of GDF-15. GDF-15 is a peptide hormone
produced by cells responding to a wide range of stressors and acts through a receptor complex
solely expressed in the hindbrain, where it suppresses appetite and thereby food intake (Coll et
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al., 2019). It was proposed through this association that metformin’s effect to lower body weight
as well as other effects in prediabetes involves the elevation of circulating levels of GDF-15
(Coll et al., 2019). In a randomized placebo-controlled trial of metformin, GDF-15 was measured
in participants without diabetes over a period of 18 months (Coll et al., 2019). Over that period,
participants receiving metformin lost significantly more weight compared to placebo and
correlated with higher levels of GDF-15 (Coll et al., 2019). It was found that weight loss was
positively correlated to the levels of plasma GDF-15 (Coll et al., 2019). In this same study, wildtype mice were given oral metformin and were shown to have increased circulating GDF-15 with
GDF-15 expression increasing predominately in the distal intestine and kidney (Coll et al.,
2019). When provided with a high fat diet and administered metformin, metformin prevented
weight gain, but not in mice lacking GDF-15 or its receptor glial-cell-line-derived neurotrophic
factor family receptor alpha like (GFRAL) (Coll et al., 2019). Essentially, metformin worked at
preventing weight gain only in mice that had the peptide hormone GDF-15.
Metformin was also found to have effects on energy intake, energy expenditure, insulin
sensitization, and insulin tolerance that all required GDF-15 (Coll et al., 2019). Metformin is the
only glucose-lowering medication or therapy that has been found to acutely increase serum
GDF-15 levels, especially in patients with insulin resistance or T2DM (Coll et al., 2019).
Knowing that GDF-15 signals through a specific receptor complex through the hindbrain to
reduce body weight and that metformin has the ability to increase GDF-15 is a major
development in the prevention or delaying of T2DM in prediabetic patients because weight loss
is one of the primary goals of prediabetic and diabetic treatment. These findings open avenues
into more research as to the role metformin plays in diabetes and beyond. According to Day et al.
(2019):
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There are currently over 1,500 registered clinical trials to test the effects of metformin in
different diseases, including cancers, cardiovascular disease and even ageing. Mice
overexpressing GDF15 have enhanced lifespan and are protected from atherosclerotic
cardiovascular disease. These phenotypes are remarkably similar to those induced by
metformin, which also reduces cardiovascular disease and potentially improves lifespan.
Therefore, the possibility that GDF15 has a causal role in multiple beneficial effects of
metformin treatment warrants further investigation (p. 1206).
These findings allow insight into why and how metformin prevents or delays T2DM in
prediabetic individuals. This knowledge has potential to inform providers who treat diabetic
patients on the best and most effective treatment options available.
Metformin Versus Lifestyle Modifications
Currently the gold standard and most practiced approach to treatment of prediabetes and
delaying progression to T2DM is lifestyle modifications, including weight loss, physical activity,
and healthy diet. It is not until the individual and disease progress to T2DM that pharmacological
interventions such as metformin are used. Research has shown that metformin is effective in
treating and sustaining T2DM. Can metformin be just as effective as lifestyle modifications in
the treatment of prediabetes, whether that be in combination or solely?
The Diabetes Prevention Program Research Group (2002) conducted one of the biggest
studies that compared lifestyle-modifications to metformin and their ability to reduce the
incidence of diabetes. There were 3,234 nondiabetic persons with elevated fasting and post-load
plasma glucose concentrations (prediabetes) that were randomly placed into a placebo,
metformin, or lifestyle-modification program (Diabetes Prevention Program Research Group,
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2002). The control group was given nothing, metformin group was prescribed metformin 850 mg
twice daily and the lifestyle-modification group was given a goal of attaining a 7 percent weight
loss and participating in at least 150 minutes of physical activity per week (Diabetes Prevention
Program Research Group, 2002). After an average 2.8 year follow-up the incidence of diabetes
was 11.0, 7.8, and 4.8 cases per 100 persons in the placebo, metformin, and lifestyle groups
which equated to a reduced incidence by 58 percent in the lifestyle group and 31 percent in the
metformin group when compared to the placebo group (Diabetes Prevention Program Research
Group, 2002). To prevent one individual from being diagnosed with diabetes in a three-year
period, 6.9 persons would have to participate in the lifestyle intervention program while 13.9
would have to receive metformin (Diabetes Prevention Program Research Group, 2002). It was
shown that lifestyle modifications and metformin both reduced the incidence of diabetes,
however, lifestyle modifications were more effective in the side by side comparison (Diabetes
Prevention Program Research Group, 2002). An interesting finding that came out of this study
was regarding compliance to the two interventions. Fifty-percent of the individuals in the
lifestyle-intervention group achieved their goal weight loss by the end of the 24 week period and
thirty-eight percent had that goal weight loss at the most recent visit which was over a year later
(Diabetes Prevention Program Research Group, 2002). Individuals who met the physical activity
goal of 150 minutes seven times a week was seventy-four percent at 24 weeks and fifty-eight
percent at the most recent visit (Diabetes Prevention Program Research Group, 2002). For the
individuals taking the placebo and metformin pills, ninety-seven and eight four percent
respectively were compliant (Diabetes Prevention Program Research Group, 2002). It is evident
that compliance with taking a daily medication was far superior then lifestyle modifications such
as health eating and physical activity and can play a key role in the success of the treatment.
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In a similar study to The Diabetes Prevention Program, 3,041 adults with hyperglycemia
were randomly selected into lifestyle, metformin, or placebo groups. The dependent variables in
this study were weight loss at 6 and 12 months; FPG at 6 months; A1C at 6 months, and postload glucose at 12 months with the main outcome being time to diabetes diagnosis (Maruthur et
al., 2013). In six months, 140 individuals developed diabetes in the lifestyle group, 206 in the
metformin group, and 258 in the placebo group (Maruther et al., 2013). In all groups, at
attainment of optimal 6-month FPG and A1C and 12-month post-load glucose predicted a greater
than sixty percent lower risk of diabetes (Maruther et al., 2013). It was found that there was
certain variable that could predict decreased diabetes risk depending on what group an individual
was assigned. For the lifestyle group, variables such as weight loss and FPG were better
predictors of decreased diabetes risk. In the metformin group, early reduction in glycemia,
looking at the variables of FPG, A1C and post-load glucose were stronger predictors of future
diabetes risk than weight loss was (Maruther et al., 2013). This information could guide
providers in management decisions based on what treatment their patient is receiving. If their
patient is participating in lifestyle intervention, then looking at variables such as weight loss and
FPG may be more important when understanding if their treatment is effective and their risk of
progressing to T2DM.
In a trail similar to the previous two, 103 participants were divided into three groups,
standard care, intensive lifestyle modification, intensive lifestyle modification and metformin
(Kulkarni et al., 2018). In this trial they variables looked at were weight, fasting blood sugar,
A1C, high-sensitivity C-reactive protein (hsCRP) (risk factor for atherosclerosis), and carotid
intima-media thickness (CIMT) after six months (Kulkarni et al., 2018). After six months, there
was a reduction in weight and fasting blood sugar in all three groups and A1C in the intensive
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lifestyle modification (ILSM)+Metformin group (Kulkarni et al., 2018). Over six months the
difference in hsCRP within the three groups were -0.12 (standard care), -0.58 (ILSM), and -.11
(ILSM+Met) (Kulkarni et al., 2018). Regarding CIMT, there was no difference between the three
groups at six months (Kulkarni et al., 2018). Interesting enough, in the standard care group there
was a significant reduction in the waist-hip ratio, LDL cholesterol, and triglycerides, which was
not seen in the other two groups (Kulkarni et al., 2018). Metformin and exercise have shown to
reduce hsCRP and other inflammatory biomarkers in prediabetes and diabetes which reduces
CVD risk (Kulkarni et al., 2018). This trial did not look solely at metformin compared to
lifestyle interventions, instead looked at the combination of the two. This data suggests that
metformin has the ability to reduce relative risk and may have the extra benefit of reducing A1C
in combination with ILSM or solely.
In a hallmark study, the UK Prospective Diabetes Study Group (1998) confirmed this
finding with their study that compared metformin with the conventional group (insulin or
sulphonyl urea therapy) and found that the metformin group had a A1C of 7.4percent compared
to 8.0percent in the conventional group (UK Prospective Diabetes Study Group, 1998). It was
also found that metformin, compared to conventional therapy, had risk reductions of 32percent
for any diabetes-related endpoint, 42percent for diabetes-related death, and 36percent for allcause mortality (UK Prospective Diabetes Study Group, 1998). Based off these findings and the
fact that metformin decreases the risk of diabetes related endpoints, is associated with less
weight gain (actually aides weight loss), and has fewer hypoglycemic attacks then other
pharmacological interventions, it was suggested that metformin be the first-line therapy (UK
Prospective Diabetes Study Group, 1998). Sheng et al., (2019) further supports that the
progression of diabetes could be delayed to varying degrees by lifestyle and pharmacological
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interventions except for angiotensin-converting enzyme inhibitors, statins, sulfonylureas and
vitamin D. “In adults with pre-diabetes, firm evidence supports the notion that lifestyle
modifications and metformin reduces the incidence of diabetes with an average of 20percent
relative risk reduction, while statins increase the relative risk 20percent” (Sheng et al., 2019, p.
1). Regarding lifestyle modifications, long-term strategies that involve three factors, nutrition,
exercise, and weight loss, contribute to an abundance of positive results such as reducing BMI,
body weight, waist and hip circumference, systolic and diastolic pressure, fasting, and 2-h
postprandial blood glucose, total cholesterol and by increasing HDL (Sheng et al., 2019).
There have been a number of clinical trials that demonstrated the effectiveness of
lifestyle and/or pharmacological therapy at preventing or delaying the progression to T2DM in
prediabetic patients, but none have looked at the other side of the spectrum and how effective
interventions are at returning prediabetic patients to normal glucose ranges (Perrault et al., 2009).
Perrault et al., (2009), examined the effect of basal biologic factors, weight change, and
prevention strategies such as intensive lifestyle intervention or metformin on the incidence of
regression from prediabetes to normal glucose range. There were two major findings in this
study. The first finding was that insulin secretion, and other biologic processes that are retained
with younger age are key in restoring prediabetics to normal glucose ranges (Perrault et al.,
2009). The other finding was that through weight loss and intensive lifestyle interventions
normal glucose ranges can be restored in prediabetic patients, meaning metformin, while
effective in preventing progression to T2DM, it is not effective in restoring normal glucose
ranges (Perrault et al., 2009). Weight loss was shown to be the most important aspect of
intensive lifestyle interventions as with every 1 kg loss there was an associated 16 percent
reduction in diabetes risk (Perrault et al., 2009). However, other aspects of intensive lifestyle
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interventions such as healthy eating and exercise also restored normal glucose ranges, though not
as effective as weight loss. There was one nonmodifiable predictor that could play a major role
in prediabetes management and that was age. Younger individuals had a greater associated with
regression to normal glucose ranges then older individuals, meaning intensive lifestyle
interventions may be more effective in the younger population and not as effective in the older
and therefore other strategies may come in play for prediabetes treatment as an individual ages
(Perrault et al., 2009).
It has been shown that lifestyle interventions reduce the relative risk of diabetes in
individuals with prediabetes but what happens when lifestyle interventions are no longer as
effective in improving glycaemia? There have only been a few studies that looked at
pharmacological effectiveness in individuals who were deemed non responders to lifestyle
interventions (Ibrahim et al., 2018). These studies found that metformin treatment was associated
with a thirty-one percent risk reduction for diabetes compared to placebo (Ibrahim et al., 2018).
They also found that other pharmacological interventions such as orlistat, pioglitazone, and
liraglutide had relative risk reduction for diabetes by thirty-seven, seventy-two, and sixty-six
percent respectively (Ibrahim et al., 2018). The major barriers with other pharmacological
interventions other than metformin is cost and side effects. When you consider the nonresponders to lifestyle interventions; young age at diagnosis of diabetes, relatively lower BMI,
high rates of insulin resistance and lower thresholds for the risk factors of diabetes and compare
metformin with lifestyle interventions that effectives becomes almost identical (Ramachandra et
al., 2006). In a study that looked at native Asian Indians who are considered to be high risk for
progression to diabetes, the effects of lifestyle modification, metformin, and lifestyle medication
with metformin were compared (Ramachandra et al., 2006). They found that the relative risk
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reduction to diabetes was 28.5 percent with the lifestyle modification group, 26.4 percent with
the metformin group, and 28.2 percent with the lifestyle modification and metformin group
(Ramachandra et al., 2006). To prevent 1 case of diabetes, you would have to treat 6.4 persons
with lifestyle modifications, 6.9 with metformin, and 6.5 with lifestyle modification and
metformin (Ramachandra et al., 2006). In individuals who are considered high risk and uniquely
present with prediabetes where BMI and weight are not major factors, metformin can play a role
in prevention progression to T2DM.
Individuals with A1C of 5.7-6.4 percent, impaired glucose tolerance, and/or impaired
fasting glycemia should all be counseled on lifestyle modifications with the goal of 7 percent
weight loss and moderate physical activity 150 minutes per week (Standards of Medical Care in
Diabetes, 2012). Metformin should be the only drug considered for pharmacological intervention
as other drugs have issues with cost, side effects and lack of research (Standards of Medical Care
in Diabetes, 2012). Even though metformin was less effective than lifestyle interventions in
certain studies, there may be cost saving over a 10-year period and metformin has shown to be
effective; (a) in individuals with a BMI of at least 35 kg/m2, (b) in women with a history of
gestational diabetes where metformin and lifestyle interventions led to a 50 percent reduction in
risk of diabetes (Standards of Medical Care in Diabetes, 2012). It is reasonable to consider
metformin usage in these individuals (Standards of Medical Care in Diabetes, 2012).
In summary, research shows that lifestyle modifications were most effective in
preventing or delaying the progression of prediabetes to T2DM, however, there were certain
scenarios where metformin can play a significant role and be equally as effective.
Safety and Tolerability
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One barrier to prescribing and administration of metformin for treatment of prediabetes is
the safety and tolerability of metformin. Common reactions of metformin are as follows:
diarrhea, nausea/vomiting, flatulence, asthenia, indigestion, abdominal discomfort, anorexia,
headache, metallic taste, and rash (Epocrates, n.d.). Serious reactions can include lactic acidosis,
anemia, and hepatotoxicity (Epocrtes, n.d.).
In a study conducted by the Diabetes Prevention Program Research Group found that
gastrointestinal (GI) symptoms were more common among metformin compared with placebo
participants, averaging 28 percent and 16 percent respectively (Diabetes Prevention Program
Coordinating Center, 2012). Metformin participants also reported “study medication-related” GI
symptoms more frequently than the placebo group (9.5percent vs. 1.1percent) (Diabetes
Prevention Program Coordinating Center, 2012). GI symptoms included diarrhea, flatulence,
nausea, and vomiting (Diabetes Prevention Program Research Group, 2002). GI symptoms did
decline throughout the study and by year 6, rates of GI symptoms were similar in the metformin
and placebo group (Diabetes Prevention Program Coordinating Center, 2012). Symptoms did
vary by race/ethnicity and sex (data not provided regarding which race/ethnicity or sex reported
higher rates of symptoms), however, overtime symptom rates became similar by demographic
group (Diabetes Prevention Program Coordinating Center, 2012). Reports of nonserious adverse
events such for hypoglycemia and anemia were uncommon, and no differences were reported
between groups (Diabetes Prevention Program Coordinating Center, 2012). There were seven
metformin and eight placebo participants that reported hypoglycemia while fifty metformin and
thirty-eight placebo participants reported anemia (Diabetes Prevention Program Coordinating
Center, 2012). Serious adverse events were even rarer with three reports for anemia (two
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metformin, one placebo) and zero for lactic acidosis (Diabetes Prevention Program Coordinating
Center, 2012).
During the Diabetes Prevention Program study, hemoglobin (Hgb) and hematocrit (Hct)
levels were closely followed and it was found that average Hgb and Hct levels were the same at
baseline and over time were slightly lower in the metformin compared to the placebo group
(Diabetes Prevention Program Coordinating Center, 2012). Again, Hgb and Hct levels varied by
race/ethnicity and sex, but overtime became similar (Diabetes Prevention Program Coordinating
Center, 2012). Percent of participants with low Hgb was not significantly different between
metformin and placebo group (11.2 percent vs. 7.6 percent) but were more different regarding
low Hct (12.6 percent vs. 8.4 percent). Hgb and Hct changes occurred during the first year with
stabilization shortly after (Diabetes Prevention Program Coordinating Center, 2012). Overall,
metformin participants did have slightly higher rates of GI symptoms and nonserious adverse
events, but these improved with time and did not ultimately affect their compliance and
adherence to the medication regimen.
When comparing metformin and lifestyle modification, GI symptoms was highest in the
metformin group, but musculoskeletal (MSK) symptoms was highest in the lifestyle-intervention
group (Diabetes Prevention Program Research Group, 2002). MSK symptoms included myalgia,
arthritis, and arthralgia. In this study, rates of other adverse events, hospitalization, and mortality
were comparable (Diabetes Prevention Program Research Group, 2002). It was concluded that
metformin and lifestyle interventions were safe in addition to being effective (Diabetes
Prevention Program Research Group, 2002). It is important to understand that with any treatment
option for prediabetes, there are side effects and risks, however, these regress as the longer the
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patient is on the medication and therefore weighing benefits, risks, and side effects is extremely
important.
Reduction in Macrovascular Complications
Individuals with diabetes mellitus and prediabetes are at an increased risk for
macrovascular complications, including coronary artery disease, atherosclerosis, and
cardiovascular disease.
Coronary heart disease (CHD) risk is doubled in T2DM mellitus and is the top cause of
morbidity and mortality in T2DM (Goldberg et al., 2017). A 1 percent increase in HbA1C was
associated with a 21 percent increased risk of CHD events and a 37 percent increase in
retinopathy or nephropathy (Newman et al., 2017). Interventions targeting dyslipidemia,
hypertension, and hyperglycemia have reduced CHD in the general population, however,
diabetes-related CHD risk remains, signifying there may be limitations to benefits of
interventions targeted at CHD in diabetics (Goldberg et al., 2017). To reduce CHD preventative
approaches, need to be addressed and initiated as early as possible, including diabetes prevention
itself (Goldberg et al., 2017).
In a study conducted with the Diabetes Prevention Program Research Group, subclinical
atherosclerosis was assessed in individuals with coronary artery calcium (CAC) (Goldberg et al.,
2017). CAC measurements are a noninvasive tool that reflects total coronary atherosclerotic
burden, helping predict CHD (Goldberg et al., 2017). Research found that in men but NOT in
women, CAC severity and presence were lower in the metformin compared with the control
group (Goldberg et al., 2017). When comparing the metformin and lifestyle group, CAC severity
and presence were similar (Goldberg et al., 2017). Race/ethnicity and age did play a role in the
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CAC severity and presence, with lower CAC being found in younger men (Goldberg et al.,
2017). No CAC differences were identified between the two groups (Goldberg et al., 2017).
Metformin reduced early stages of plaque development in men and CHD events compared with
diet and sulfonylurea placebo groups, suggesting that metformin may be beneficial in preventing
coronary atherosclerosis in prediabetic patients (Goldberg et al., 2017). In a recent treatment
program using metformin in subjects with HIV infection and metabolic syndrome, it was found
that metformin reduced CAC progression compared to a placebo group (Goldberg et al., 2017).
Of note, there was a gender difference in the effect of metformin on CAC that was
observed in this study but has not been observed in other studies. In women, CAC severity was
lower, making it harder to study the effect of metformin (Goldberg et al., 2017). More than half
of the women in the study had measurable CAC levels yet metformin did not have an effect on
CAC presence (Goldberg et al., 2017). In this study, 36 percent of women were premenopausal,
and it is known that atherogenesis proceeds more slowly in premenopausal women, contributing
to the lack of effect of metformin in women (Goldberg et al., 2017).
There was no reduction in the prevalence of clinically significant CAC in men that had
high CAC levels compared with placebo group, meaning the effects of metformin were more
paramount with lower levels of CAC (Goldberg et al., 2017). Lower CAC scores are associated
with a significant increase in CHD event rate, implying that metformin has a greater effect when
the individual has smaller and recently calcifying plaques rather than well-established lesions
which would support the evidence that metformin has a greater effect on CAC severity in
younger men (Goldberg et al., 2017). This could mean that metformin has less clinical efficacy
in older men, but more testing would have to be conducted before this could be determined.
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Of importance, lower CAC in the metformin group was noted regardless of whether
diabetes mellitus had developed (Goldberg et al., 2017). There has been question whether
metformin was effective in reducing vascular complications before the development of T2DM
regardless of its ability to delay diabetes development and its use in prediabetes. Based on the
information presented above, the sooner metformin is started before or after diabetes diagnosis
the more of a beneficial effect it has on early stages of atherosclerosis in men, though more
research is needed regarding its effect in women (Goldberg et al., 2017).
Even though macrovascular complications such as CAD is the leading cause of mortality
and morbidity for patients with T2DM, there is a lack of research or evidence regarding
metformin’s role and ability to reduce those macrovascular complications. Metformin has been
proven to reduce weight gain, improve glycemic control, and reduce insulin requirements, which
all may have a direct benefit on reducing CHD and macrovascular complications.
Barriers to Metformin Prescribing
Metformin has been shown through research that it can be an effective new therapy for
the treatment of prediabetes and progression to T2DM, yet Metformin continues to be under
prescribed and underutilized in this population. The reasons as to why metformin use remains
low are not entirely clear, however, research has set its sights on the front lines, trying to
understand the barriers providers face when prescribing metformin for treatment of prediabetes.
In a study that estimated the rates of prevalence, diagnosis, and treatment of impaired
FPG (IFG) and impaired glucose tolerance (IGT) found that approximately 34.6 percent of the
United States population met the criteria for prediabetes diagnosis and that life-style
modification and metformin reduced the incidence of T2DM by 58 percent and 38 percent
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respectively in just 3 years (Karve & Hayward, 2010). Yet, only 3.4 percent of the 34.6 percent
of the individuals meeting prediabetes criteria reported that their physicians diagnosed them with
prediabetes (Karve & Hayward, 2010). None of those individuals reported receiving metformin
(Karve & Hayward, 2010). In a study that examined metformin prescription for diabetes
prevention and patient characteristics that may affect metformin prescription, reported better
results, suggesting that 3.7 percent of insured, working-age adults with prediabetes, were
prescribed metformin over a three-year period (Moin et al., 2015). It was found that the
prevalence of metformin prescription was higher among patients with a history of gestational
diabetes or a BMI < 35 kg/m2, but that was still only at 7.8 percent (Moin et al., 2015). Meaning
less than 1 of 12 high-risk patients, who met criteria based off national guidelines, received
metformin (Moin et al., 2015). This extremely low rate is concerning given the significant
benefits metformin potentially can offer patients.
There are theories as to the extremely low metformin prescription rate such as physicians
do not emphasize the importance of prediabetes to their patients, physicians do not adequately
screen for and diagnose prediabetes, physicians do not recommend lifestyle modification to
prediabetic patients any more intensively than normoglycemia subjects, physicians are unaware
of metformin’s benefits or they are aware of the benefits, but find them unconvincing (Karve &
Hayward, 2010). Tseng (2017), found that six percent of providers were able to correctly identify
all the risk factors that should trigger screening. On average, providers were able to identify 8 out
of the 11 risk factors with the most commonly identified risk factors being family history,
overweight, history of gestational diabetes, dyslipidemia, hypertension, and history of heart
disease (Tseng et al., 2017). The least-commonly identified risk factors were Hispanic and Asian
ethnicity (Tseng et al., 2017). A total of 17 percent of providers were able to identify the
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laboratory parameters for diagnosing prediabetes based on both FPG and A1C (Tseng et al.,
2017). Family medicine and medicine-pediatric providers were able to correctly identify the
parameters more often than internal medicine providers (Tseng et al., 2017). When patients were
diagnosed with prediabetes, 90 percent of providers did report close follow-up with them, often
seeing their patients with 6 months of diagnosis (Tseng et al., 2017). As far as a management
approach, one-quarter of providers selected the correct value regarding the minimum amount of
weight loss recommended and nearly 30 percent answered they did not know (Tseng et al, 2017).
Less than half of the providers selected the right answer regarding the recommended minimum
amount of physical activity and when asked to identify the best recommended initial
management approach only 11 percent selected a referral to a behavioral weight loss program,
while 96 percent selected educating patient on diet and physical activity (Tseng et al., 2017).
Providers agreed that diagnosing prediabetes is important regarding their patients’ health
and that lifestyle modification minimizes that progression, but providers disagreed that
metformin could do the same (Tseng et al., 2017). Lack of motivation, patient’s physical
limitations in doing activity, and lack of weight or nutrition resources were all selected as
barriers to lifestyle modifications and providers feel as though they need more time for
counseling, more educational resources for patients, improved nutrition resources, and access to
weight loss programs to improve prediabetes management (Tseng et al., 2017). Providers feel as
though patient’s avoidance of medications, pharmacological side effects, and anticipated poor
adherence are barriers to metformin use in prediabetes, NOT medication cost or lack of FDA
approval for metformin use in prediabetes (Tseng et al., 2017).
These findings highlight concern about translation of decade-old evidence support the use
of metformin in treatment of prediabetes and diabetes prevention (Moin et al., 2015). The lack of
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translation of a safe, evidence-based therapy for a highly prevalent epidemic is a public health
nightmare (Moin et al., 2015). While lifestyle modification can be cost-effective, metformin has
the potential to be cost saving (Moin et al., 2015). Ideally, all patients who meet diagnostic
criteria would be diagnosed with prediabetes and all of them would pursue lifestyle
interventions. Research is showing that this is simply not true. Minimally, patients should be
educated about the potential benefits of metformin and should be offered this option as
preventative treatment (Moin et al., 2015). However, before anything can be done, providers
need to be educated regarding risk factors, screening, diagnosis, management, and treatment of
prediabetes. According to Tseng (2017):
PCPs had substantial gaps in knowledge about prediabetes that need to be addressed for
interventions, such as the CDC prediabetes screening and prevention campaign, to be
successful. Educating providers on screening guidelines, diagnostic criteria and
management options will be the important first step to filling these gaps. The role of
professional societies in improving knowledge and addressing attitudes cannot be
underestimated. Systems changes to support provider behavior are also important.
Despite substantial evidence for the effectiveness of DPPs, they remain underutilized.
Reasons for this are likely complex and warrant further investigation. Expanding
insurance coverage and the availability of these high quality, comprehensive programs
are essential. With these changes, PCPs are optimally positioned to take a lead in curbing
the diabetes epidemic (p. 1177).
Special Population Needs
Primary treatment goal for prediabetes is to normalize glucose and prevent the
progression to diabetes and microvascular complications (AACE, n.d.). Therapeutic lifestyle
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management through medical nutrition therapy (MNT), physical activity, and weight loss is the
first choice in management for prediabetes. However, there are special populations that may
benefit more from the addition of metformin due to their unique barriers that do not allow
lifestyle interventions to be as effective.
In a study conducted by the Diabetes Prevention Program Research Group (2002),
lifestyle intervention alone was least effective in older participants due to their physical
limitations, which means there needs to be a consideration regarding whether a patient can
participate effectively in lifestyle interventions to make a difference. It was suggested that older
patients my need to have metformin added to their treatment regimen early on due to their
physical limitations (Diabetes Prevention Program Research Group, 2002). There are populations
that have physical, cognitive or both barriers that can significantly limit their ability to
participate in physical activity or follow a strict regimented diet plan. With these specific and
unique populations, metformin may be a more appropriate first line therapy then lifestyle
interventions.
Another finding was that metformin was less effective in persons with a lower BMI or a
lower FPG concentration, meaning the effectiveness of metformin may increase with FPG
concentration and how advanced the individual is in their diabetes (Diabetes Prevention Program
Research Group, 2002). Now, this does not mean that an individual has to have a high BMI or
high FPG concentration for metformin to be effective, it means that metformin tends to be more
effective when the more advanced the disease is. This is an important point because metformin
does have an added cost and therefore the patient may not get their bang for their buck if they are
borderline prediabetic. If a patient has a relatively low BMI and low FPG concentration but still
considered prediabetic, the more cost-effective treatment may be lifestyle modifications. In
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contrast, if an individual has a high BMI and high FPG concentration and is considered
prediabetic, metformin may be the more cost-effective treatment.
There is also evidence that metformin should be strongly considered for patients who are
younger than 60 years of age, those with a BMI over 35 kg/m2, or those with a history of
gestational diabetes (Moin, 2015). Nathan (2007) elaborates on that point more by stating
patients with elevated IFG and IGT and any of the following: under 60 years of age, BMI over
35 kg/m2, family history of diabetes in first-degree relatives, elevated triglycerides, reduced
HDL cholesterol, hypertension, A1C greater than 6.0 percent should be treated with lifestyle
modifications and/or metformin. When prescribing to any individual it is important to keep in
mind that while metformin has been proven to be safe to take, precautions should be taken in
patients with renal or hepatic insufficiency.
Ethnicities, such as Asian Indians, Asian American, African American, Alaska Native,
American Indian, Hispanic/Latino, Native Hawaiian, or Pacific Island that have a very high
progression rate of IGT to diabetes, meaning they are at a high risk of progressing to T2DM if
diagnosed with prediabetes. Individuals who are from these ethnicities may benefit from early
intervention with metformin due to being considered high risk of progressing to T2DM solely
due to their ethnicity (Ramahandran, 2006).
In summary, while lifestyle interventions such as weight loss, exercise, and dietary
modifications are considered first line treatment for prediabetes, there are unique circumstances
and populations where barriers to lifestyle interventions present themselves. In these populations,
metformin should be considered in addition to or first line treatment for prediabetes. However,
weight loss, exercise, and dietary modifications should always be addressed and individualized.
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Discussion
According to the Centers for Disease Control and Prevention (2019), 84 million
American adults have prediabetes. Prediabetes increases an individual’s risk of developing
T2DM, heart disease, and stroke (CDC, 2019). Lifestyle changes such as weight loss, increasing
physical activity and dietary modifications are the first route to preventing prediabetes from
escalating into diabetes type 2 or at least delaying the progression. While lifestyle changes have
been the gold standard for quite some time, there is still a T2DM epidemic occurring and
therefore providers and society are looking for other avenues to help fight the epidemic. When
lifestyle modifications fail to provide us with the necessary results and individuals continue to
have high glucose levels, where do we turn? In cases where an individual has prediabetes and are
considered to be at a high risk for T2DM, recent guidelines recommend considering use of
metformin, especially for patients who are under 60 years old, have a BMI over 35 kg/m2, or
have a history of gestational diabetes (JAMA, 2017). Metformin used historically for patients
with active T2DM can play a role in preventing prediabetes from progressing to T2DM and
developing complications.
As you can see, there are a lot of factors that play a role in the screening, diagnosing, and
treatment/management of prediabetes to prevent or delay progression to T2DM. The question
that was to be answered through this systematic review of literature was: For adults with
Prediabetes, does the use of metformin reduce the future risk of developing T2DM Mellitus and
vascular complications when compared to the usual practice of lifestyle modification alone?
Through the literature review, the answer to this question is not black and white. While there is
no denying that lifestyle interventions such as weight loss, physical activity, and healthy eating
are effective in the treatment/management of prediabetes, metformin does play a role. Yes,
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metformin does reduce the risk of developing T2DM compared to the usual practice of lifestyle
modification, but is more effective in certain populations such as individuals with physical
limitations where physical exercise is not as easy, individuals who are considered high and
individuals who do not fit the typical “diabetes mold” (young age of onset of diabetes, a
relatively lower BMI, with high rates of insulin resistance and lower thresholds for the risk
factors for diabetes). In these individuals, lifestyle modification should still be considered the
gold standard, though metformin should be considered as an additional option for treatment.
Although diet and physical activity are effective, the sole reliance on such will not be enough,
especially for patients who are high risk (Cefula, 2016). Pharmacological interventions, such as
metformin, are going to need to be implemented and we cannot rely solely that diet and physical
activity will be enough (Cefula, 2016). With the fast-paced life that many adults are living and
the constant stress from work and raising a family, adults do not have the time, money, or
ambition to commit to the recommended lifestyle modifications. Even though lifestyle
modifications are considered the gold standard, they may not be realistic for all. In an ideal
world, our diabetic patient would eat healthy and participate in moderate to strenuous activity
150 minutes a week, but many fail to make sufficient or sustained lifestyle changes. Improved
success may be achieved by designing a treatment plan that fits into everyday life and is
sustainable.
It is important to understand patients outside of the office and examine their everyday
lives. For patients with significant time commitments and restraints that make lifestyle changes
challenging, metformin may provide them with prevention strategies to avoiding the progression
into T2DM. This does not mean stop educating prediabetic patients on lifestyle interventions
such as weight loss, exercise, and dietary modifications. Rather, seek to understand that patients
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are humans who have lives beyond the doctor’s office and in an ideal world they would eat right
and exercise the right amount, but that is not the reality. Instead, meet your patient where they
are at and do not set them up for failure and be a bystander as they progress into T2DM when
you knew from the beginning that lifestyle interventions were going to be hard for them. It is
important to educate regarding lifestyle interventions and allow your patients to try that, but it is
also important to help them gain control of their health and metformin may provide that for
them.
Implications for Future Practice
Recommendations for Clinical Practice
Metformin is under prescribed and underutilized. The lack of awareness of how serious
prediabetes is and the associated risks (micro and macrovascular complications) is scary and puts
our patients and population at high risk. There is speculation that since metformin is not
approved by the U.S. FDA for prediabetes, providers are hesitant to prescribe it, but research is
showing the opposite. There is a knowledge gap at the front lines that we need to combat. We
cannot simply wait for the U.S. FDA to approve metformin for the treatment of prediabetes, we
are in an epidemic right now and if we wait, it will be too late. Although the reasons are not
entirely clear, providers lack of knowledge creates a barrier to broader implementation. Closing
the knowledge gap for providers regarding screening, diagnosing, and treatment/management of
prediabetes has to be at the forefront. Clearer guidelines regarding when to screen patients and
who is considered at high risk need to be developed. If metformin is shown to be effective in the
treatment of prediabetes, guidelines have to reflect this (Wang et al., 2013). Universal screening
is needed. “Noninvasive risk scores should be used in all countries, but they should be locally
validated in all ethnic populations focusing on cultural differences around the world” (Ibrahim et
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al., 2018, pg. 8). Currently metformin is not approved by the U.S. FDA for prediabetes and
therefore may be creating hesitancy to prescribe it “off label” (Moin et al., 2015). High priority
needs to be placed on the management of prediabetes. Media campaigns to increase awareness of
prediabetes and its consequences if left untreated could be a start to increasing public awareness.
Other strategies to increase awareness and promote informed decision making include,
clinical decision-making tools and physician directed and performance-based incentive programs
(Moin et al., 2015). Cefalu et al., (2016) states that an early step in advancing preventative
strategies for diabetes medical community is to reach an agreement on how to implement
programs on a global level. Developing clear guidelines that help providers identify individuals
at high risk, when to screen, diagnostic criteria, and treatment/management are necessary. These
guidelines also need to pay special attention to pharmacological interventions and acknowledge
their benefits in treatment of prediabetes (Cefalu et al., 2016). Understanding an individual’s
perspectives and preferences is essential to managing prediabetes, but also understanding the
providers’ perspectives and preferences will provide us with insight as to where the barriers lie
and if there is a disconnect between provider and patient.
Recommendations for Research
More research needs to be conducted regarding provider perceived barriers to
pharmacological treatment, including metformin and patient perceived barriers to
pharmacological treatment and lifestyle interventions. There needs to be an understanding of
potential barriers to wider adoption of this safe, tolerable, evidence-based, and cost-effective
prediabetes therapy (Moin et al., 2015). More research regarding compliance of pharmacological
and lifestyle interventions and how compliance factors in regarding treatment success.
Metformin is not the only pharmacological intervention and therefore future research may
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include other medications if they prove to be effective, have a good safety profile, are tolerable,
and are of relatively low cost (Nathan et al., 2007). Questions regarding benefits of metformin
and lifestyle modifications need to be answered. Continuing to follow-up on study participants
and analyzing secondary outcomes can help us gain insights into whether glucose concentrations
can be maintained at levels below diagnostic criteria and the long-term outcomes (Diabetes
Prevention Program Research Group, 2002). There is insufficient evidence regarding the costeffectiveness of treatment strategies for prediabetes and therefore, research is needed on the
long-term cost savings for starting metformin early in prediabetic care. Research, thus far
regarding prediabetes has included small sample sizes, relatively healthy prediabetes, and short
follow-ups which provides us with only a fraction of information as prediabetes and T2DM can
often be lifelong disease and therefore continued research with longer follow-up with adequate
sample size could help reassess effects and understand long term effects of interventions
(Kulkarni et al., 2018).
Conclusion
Prediabetes has reached epidemic proportions with no signs of slowing. Prediabetes
places individuals at an increased risk for T2DM and the associated micro and macrovascular
complications. Currently, lifestyle interventions, such as weight loss, physical activity, and
healthy diet are the gold standard of prediabetes and T2DM. However, pharmacological
interventions have been gaining attention for their efficacy in the treatment of T2DM. This
logically leads to questions regarding their role in prediabetes treatment and the prevention or
delaying of T2DM. Research has found that lifestyle interventions and metformin are effective in
decreasing the incidence of T2DM, although lifestyle interventions have remained most
effective. However, most of the research has encompassed small sample sizes with relatively
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healthy participants, in unrealistic situations. Our health care system needs to shift from being
reactive to proactive. It is clear that we cannot continue to rely solely on lifestyle interventions to
control this epidemic. Instead, deploying the evidence surrounding metformin use, in
combination with lifestyle interventions can strengthen efforts toward combating the epidemic.
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Table 4
Literature Review Tables of All Studies Included
Reference

Study Purpose

American Diabetes
Association. (2012).
Standards of medical care
in diabetes-2012.
Diabetes Care, 35, S1163.

Recommendations
for medical care of
diabetes

Pop(p)/S
ize(n)/Se
tting(s)
N/A

Level of
Evidence/
Design
Expert
Opinion
Level VII

Variables/Instr
uments

Findings

N/A

individuals who have
prediabetes should receive
individualized MNT as needed
to achieve treatment goals,
preferably provided by a
registered dietitian familiar

Implications
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with the components of
diabetes MNT
Weight loss is recommended
for all overweight or obese
individuals
At the time of T2DM diagnosis
initiate metformin therapy
along with lifestyle
interventions, unless metformin
is contraindicated
In newly diagnosed T2DM
patients with markedly
symptomatic and/or elevated
blood glucose levels or A1C
consider insulin therapy, with
or with-out additional agents,
from the outset
If noninsulin monotherapy at
maximal tolerated dose does
not achieve or maintain the
A1C target over 3–6 months
add a second oral agent, a GLP1 receptor agonist, or insulin

Cefalu, W., Buse, J.,
Tuomilehto, J., Fleming,
G., Ferrannini, E.,
Gerstein, H., Bennett, P.,
Ramachandran, A., Raz,
I., Rosenstock, J., &
Kahn, S. (2016). Update
and next steps for realworld translation of
interventions for type 2
diabetes prevention:
Reflections from a

Summary of seminal
prevention trials
Discussion of
considerations for
selecting appropriate
populations for
intervention and
diagnostics
Outline knowledge
gaps

N/A

Expert
Opinion
Level VII

N/A

Preventive pharmacology has
been proposed as a adjunct to
lifestyle modification due to
cost, reimbursement, and
shortage of lifestyle coaches
Metformin the only drug that
has been studied long term and
shown to be effective

Early step in advancing preventive
strategies for the diabetes medical
community is to reach an agreement on
how to approach programs that can be
implemented on a global level. How do
we design and implement diabetic
prevention programs for prediabetes that
are general enough to be implemented
anywhere and in any setting

TZD have serious adverse
events documented

Although diet and physical activity are
effective, the sole reliance on such will

54
diabetes care editors
expert forum. Diabetes
Care, 39(7), 1186-1201.
https://doi.org/10.2337/dc
16-0873

Explore new avenue
for securing
regulatory approval
of a preventionrelated indication for
metformin

Newer obesity and diabetes
medications such as orlistat and
glucagon-like peptide 1
receptor agonists, have
potential to be effective but are
costly, some are injectable, and
all require further studies.
Making metformin at the
moment, the best option for
widespread use due to its
proven effectiveness, long-term
safety and cost-effectiveness.

Specific
considerations for
pharmacological
interventions to delay
onset of T2DM

not be enough, especially for patients who
are high risk. Pharmacological
interventions are going to need to be
implemented and we can’t rely solely that
diet and physical activity will be enough
Attention needs to be given to
pharmacological interventions and
acknowledge their benefits in treatment of
prediabetes
FDA approval for a new indication of
metformin as prevention for T2DM
would be a start

Metformin use has been
minimal due to GI side effects
and lack of perceived benefit,
even though studies have
shown to be beneficial
After 3 years, diabetes risk was
reduced by 28.5, 26.4, and
28.2percent in the lifestyle,
metformin, and combination
groups

Coll, A., Chen, M.,
Taskar, P., Rimmington,
D., Patel, S., Tadross, J.,
Cimino, I., Yang, M.,

Understand the
connection between
metformin and

n = 173
adults

Randomize
d, doubleblinded,
placebo-

Randomized 1:1
to 850mg
metformin or
matched placebo

In the follow-up DPP
Outcomes Study, cumulative
diabetes incidence rates still
differed significantly 10 years
(34 and 18percent for lifestyle
and metformin compared with
placebo, respectively) and 15
years (27 and 17percent,
respectively) after initial
randomization into the DPP
Those who were allocated
metformin lost significant
weight and their levels of
GDF15 were persistently

For metformin to work properly it needs
to increase the circulating levels of
GDF15. The ability of metformin to aid
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Welsh, P., Virtue, S.,
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P., Morrow, M.,
Gutgesell, R., Lu, R.,
Raphenya, A., Kabiri, M.,
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Gerstein, H., & Steinberg,
G. (2019). Metformininduced increases in
GDF15 are important for
suppressing appetite and
promoting weight loss.
Nature Metabolism, 1,
1202–1208.
https://doi.org/10.1038/s4
2255-019-0146-4
Diabetes Prevention
Program Coordinating
Center. (2012). Long-term
safety, tolerability, and
weight loss associated
with metformin in the
diabetes prevention
program outcomes study.

circulating levels of
GDF15

controlled
trial

twice daily with
meals. Attended
six monthly
visits after
overnight fasts
and before taking
their morning
dose of
metformin.
Blood samples
collected.

elevated compared to placebo.
9

in weight loss is beneficial to its overall
effectiveness.

NA

Metformin induces expression
and secretion of growth
differentiating factor 15
(GDF15).

An increase in serum GDF15 associated
with weight loss in patients with T2DM
who take metformin.

Randomize
d doubleblind
clinical
trial

1,073 randomly
assigned to
metformin arm
and 1,082 to the
placebo arm

Gastrointestinal symptoms
more common in metformin
than placebo participants but
these symptoms declined
overtime

Level II

Participants were
≥ 25 years of

Hemoglobin and hematocrit
levels slightly lower in

Level II

Determine if
metformin increases
the secretion of a
hepatocyte-derived
endocrine factor that
communicates with
the central nervous
system

n = 16

Examine long-term
safety and tolerability
along with weight
loss and change in
waist circumference

n = 3,234
participa
nts

Randomize
d control
trial
Level II

56
Diabetes Care, 35(4),
731-737.
https://doi.org/10.2337/dc
11-1299

age, had a BMI ≥
24 kg/m2,
elevated fasting
glucose, and
impaired glucose
tolerance 2 h
after a 75-g oral
glucose load
Excluded for
prior diagnosis
of diabetes or
conditions or
medication that
would impair
ability to
participate or
affect weight
loss
Metformin or
matching
placebo initiated
at 850 mg once
daily and
increased by 1
month to 850 mg
BID unless GI
symptoms
warranted longer
titration period
Standard
lifestyle
recommendation
s, and written
information on
healthy
eating/weight,
and physical

metformin then placebo
participants but this was only
observed in first year and no
further changes occurred
Body weight and waist
circumference decreased in
metformin then placebo
participants (2.06 vs 0.02, 2.13
vs 0.79)
During unblinded part of trial,
weight loss was significant in
the metformin versus placebo
group which was related to the
degree of continuing metformin
adherence
Metformin reduced the
development of diabetes by
31percent over an average of
2.8 years

57
activity provided
annually

Diabetes Prevention
Program Research Group.
(2002). Reduction in the
incidence of type 2
diabetes with lifestyle
intervention or
metformin. The New
England Journal of
Medicine, 346(6), 393403.
https://doi.org/10.1056/N
EJMoa012512

Modifying factors
that place an
individual at risk for
diabetes through
lifestyle-intervention
program or
administration of
metformin will
prevent or delay
development of
diabetes

n = 3,234

Randomize
d Control
Trial
Level II

Weight
measured twice
yearly and waist
circumference
annually
Intervention 1 –
standard lifestyle
recommendation
s plus metformin
at a dose of 850
mg twice daily
Intervention 2 –
standard lifestyle
recommendation
s plus placebo
twice daily
Intervention 3 –
intensive
program of
lifestyle
modification
(achieve
and maintain a
weight reduction
of at least 7
percent of initial
body weight
through a healthy
low-calorie, lowfat diet and to
engage in
physical activity
of moderate
intensity, such as
brisk

Average follow-up was 2.8
years
Incidence of diabetes was as
follows; intervention 1 (7.8),
intervention 2 (11.0), and
intervention 3 (4.8) per 100
persons
Lifestyle intervention reduced
incidence of diabetes by
58percent in intervention 3 and
31percent in intervention 1
Lifestyle modification more
effective than metformin
To prevent one case of diabetes
6.9 persons would have to
participate in lifestyleintervention program and 13.9
would have to receive
metformin

Lifestyle modification and metformin are
effective at preventing or delaying
diabetes no matter gender, race or
ethnicity.
Lifestyle modification compared to
metformin was more effective at
preventing or delaying diabetes, although
both were effective
Lifestyle intervention was LEAST
effective in older participants and
therefore need to consider whether a
patient can participate effectively in
lifestyle interventions to make a
difference. Older patients may need to
have the metformin component added due
to their physical limitations
Metformin was less effective in persons
with a lower base-line body mass
Index or a lower fasting plasma glucose
concentration than in those with higher
values for these variables – the
effectiveness of metformin may increase
with fasting glucose concentration and
how advanced diabetes is
Rate of gastrointestinal symptoms was
highest in the metformin group and the
rate of musculoskeletal symptoms was
highest in the lifestyle-intervention group

58
walking, for at
least 150 minutes
per week)
Primary outcome
was diabetes
based off annual
oral glucosetolerance test or
semiannual
fasting plasma
glucose test
Self-reported
levels of leisure
physical activity
were assessed
annually with the
Modifiable
Activity
Questionnaire
The physicalactivity level was
calculated as the
product of the
duration and
frequency of
each activity (in
hours per week),
weighted by an
estimate of the
metabolic
equivalent of that
activity (MET)
and summed for
all activities
performed, with
the

– understand the whole picture where one
intervention may be more appropriate
(such as if a patient already has
musculoskeletal issues or symptoms, will
lifestyle only intervention by effective?)
benefits would depend on whether
glucose
concentrations could be maintained at
levels below those that are diagnostic of
diabetes and whether the maintenance of
these lower levels improved the long-term
outcome – questions that need to be
answered for future research
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Fujii, R., Junqueira, M.,
Restrepo, M., & Turatti,
L. (2015). Metformin and
intensive lifestyle
intervention for prediabetes – systematic
review of efficacy. Value
in Health, 18(3), 55-56.
https://doi.org/10.1016/j.j
val.2015.03.326
Goldberg, R. B., Aroda,
V. R., Bluemke, D. A.,
Barrett-Connor, E.,
Budoff, M., Crandall, J.
P., Dabelea, D., Horton,
E. S., Mather, K. J.,
Orchard, T. J., Schade,
D., Watson, K., &
Temprosa, M. (2017).
Effect of long-term
metformin and lifestyle in
the diabetes prevention
program and its outcome
study on coronary artery
calcium. Circulation,
136(1), 52–64.
https://doi.org/10.1161/CI
RCULATIONAHA.116.0
25483
Ibrahim, M., Tuomilehto,
J., Aschner, P., Beseler,
L., Cahn, A., Eckel, R. H.,
Fischl, A. H., Guthrie, G.,
Hill, J. O., Kumwenda,
M., Leslie, R. D., Olson,

Evaluate efficacy and
safety of metformin
versus intensive
lifestyle intervention
for the treatment of
prediabetes

How diabetes
prevention
interventions
(lifestyle
modification and
metformin) reduced
coronary heart
disease risk

n = 11

Systematic
Review of
RCTs
Level I

n = 3234
subjects
with
prediabet
es

result expressed
as the average
MET-hours per
week for the
previous year
Databases
included
PubMed/MEDLI
NE, Cochrane
Library,
LILACS, and
CRD.

Randomize
d control
trial

Diabetes
Prevention
Program

Level II

Diabetes
Prevention
Program
Outcome Study

Intensive lifestyle intervention
and metformin reduced
incidence of T2DM but didn’t
demonstrate that combination
of both did so.
Intensive lifestyle intervention
and metformin reduced
incidence of T2DM, but
lifestyle was more effective
No CAC differences between
lifestyle and placebo groups in
either sex.

Intensive lifestyle intervention and
metformin can provide significant results.
Treatment choice should balance benefits
and adverse effects while integrating
patient’s personal values and feasibility of
each intervention.

Metformin may protect against coronary
atherosclerosis in prediabetes among men

CAC severity and presence
lower among men in the
metformin versus placebo
groups, but no effect seen in
women.

Subclinical
atherosclerosis
assessed with
coronary artery
calcium
measurements

Primary prevention
of T2DM achievable
through
implementation of
early and sustainable
measures, including

N/A

Commentar
y/Expert
Opinion
Level VII

N/A

Lifestyle interventions (healthy
diet, physical activity, and
weight control) are needed for
prevention of diabetes.

Mobile phones help facilitate
communication between health
professionals and general population

60
D. E., Pozzilli, P., Weber,
S. L., & Umpierrez, G. E.
(2018). Global status of
diabetes prevention and
prospects for action: A
consensus statement.
Diabetes/Metabolism
Research & Reviews,
34(6), 1.
https://doi.org/10.1002/d
mrr.3021
Karve, A., & Hayward, R.
A. (2010). Prevalence,
diagnosis, and treatment
of impaired fasting
glucose and impaired
glucose tolerance in
nondiabetic U.S. adults.
Diabetes Care, 33(11),
2355-9.
https://doi.org/10.2337/dc
09-1957

nutrition education,
weight loss, physical
activity, and
medications.

Kulkarni, S., Xavier, D.,
George, B., Umesh, S.,
Fathima, S., & Bantwal,
G. (2018). Effect of
intensive lifestyle
modification & metformin
on cardiovascular risk in
prediabetes: A pilot
randomized control trial.
Indian Journal of Medical
Research, 148(6), 705712.
https://doi.org/10.4103/ij
mr.IJMR_1201_17

Research the effects
of exercise and
metformin on highsensitivity C-reactive
protein (hsCRP) and
carotid intima-media
thickness (CIMT)
which are markers for
atherosclerosis and
CVD in prediabetes
patients, as these are
often complications
of T2DM

Risk scores need to be assessed.
Inclusion criteria should be
based on combination of risk
factors and available resources.

Noninvasive risk scores should be used
but validated locally for cultural
differences in all ethnic populations
Lifestyle interventions reduce
progression, however there are studies
that show benefits of pharmacological
prevention as well.

Estimate rates of
prevalence,
diagnosis, and
treatment of impaired
fasting glucose and
impaired glucose
tolerance

n = 1,547

Crosssectional
survey
Level V

n = 103

Randomize
d Control
Trial
Level II

The National
Health and
Nutrition
Examination
Survey
(NHANES)
Multivariate
regression
analysis used to
identify
predictors of
diagnosis and
treatment
103 participants
were
randomized. 33
were assigned to
the standard arm
(STD), 35 to the
intensive
lifestyle
modification arm
(ILSM), and 35
to the intensive
lifestyle
modification
plus metformin

34.6percent had prediabetes.
4.8percent reported receiving a
formal diagnosis. None
received oral
antihyperglycemics and
exercise was recommended for
31.7percent while 33.5percent
were recommended diet
modification.

Knowing that interventions greatly reduce
progression from IFG/IFT to T2DM,
individuals are still underdiagnosed and
undertreated.
PCPs may be unaware of evidence,
unconvinced by evidence or unclear
regarding criteria. Education to PCPs
needs to occur

19.4percent had IFG,
5.4percent had IGT, 9.8percent
had both
At six months there was a
reduction in weight and fasting
blood sugar in all three arms
Reduction in A1C only in the
intensive lifestyle treatment and
metformin arm
Difference in hsCRP for STD
was -.12, ILSM was -.58, and
ILSM + Met was -.11 over six
months
At six months there was no
difference between the three

Weight reduction and FBS reduction
occurred in all three arms, meaning
lifestyle modification and metformin play
active roles in treatment of prediabetes
There was no difference seen in hsCRP
and CIMT in intensive lifestyle
modification and metformin arms, which
is contrary to other studies, but this could
be due the inclusion of patients who were
normoglycaemic and recently turned
dysclycaemic within the previous year
(meaning they were relatively new
prediabetes)

61
arm (ILSM +
Met)

arms for hsCRP, CIMT (right),
CIMT (left)

Followed up at 6
months

Trial was only conducted over a 6-month
period which is a short duration to
analyze changes – usually require at least
a year
Wasn’t a significant difference in hsCRP
levels across three arms, which is similar
to other studies outcomes, but
interventions with metformin and
exercise have shown to reduce hsCRP
and other inflammatory biomarkers in
prediabetes which reduces CVD – again
this could be seen if trial spanned over a
year rather than 6 months

Radiologist used
a high-resolution
B-mode carotid
artery ultrasound
to measure
intima-media
thickness of the
posterior walls of
bilateral
common carotid
arteries at two
different sites

Longer follow up with adequate sample
size could help re-assess the effects of
these interventions in the future and to
confirm findings

hsCRP was
measured using
an
immunoturbidim
etric assay

Maruthur, N. M., Ma, Y.,
Delahanty, L. M., Nelson,
J. A., Aroda, V., White,
N. H., Marrero, D.,
Brancati, F. L., & Clark,

Quantify relationship
between early
measures of weight
and glucose and
subsequent diabetes

n = 3,041
adults
n = 1,018
to

Randomize
d
controlled
trial

Metformin (500
mg) tablets were
provided from a
single batch.
Tablets were
repackaged in
similar packs
with appropriate
labelling and
instructions.
Independent
variable included
weight loss at 6
& 12 months,
fasting glucose

After 6 months, 604
participants developed diabetes
Lifestyle = 140
Metformin = 206

Lifestyle intervention predicts lower
diabetes risk for weight and glucose at 6
and 12 months
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J. M. (2013). Early
response to preventive
strategies in the Diabetes
Prevention Program.
Journal of General
Internal Medicine, 28(12),
1629–1636.
https://doi.org/10.1007/s1
1606-013-2548-4

in patients
undergoing diabetes
prevention
interventions

Moin, T., Li, J., Duru, O.
K., Ettner, S., Turk, N.,
Keckhafer, A., Ho, S., &
Mangione, C. M. (2015).
Metformin prescription
for insured adults with
prediabetes from 2010 to
2012: A retrospective
cohort study. Annals of
Internal Medicine, 162(8),
542–548.
https://doi.org/10.7326/M
14-1773

Examine metformin
prescription for
diabetes prevention
and patient
characteristics that
may affect metformin
prescription

lifestyle
group

Level II

n = 1,036
to
metformi
n group
n = 987
to
placebo
group
n=
17,352

and hemoglobin
A1c at 6 months,
and post-load
glucose at 12
months.
Outcome = time
to diabetes
diagnosis

Retrospecti
ve Cohort
Study
Level IV

Placebo = 258
If patients obtained optimal 6month FG & A1C and 12month post-load glucose they
had > 60percent lower diabetes
risk

Examined data
from 2010 to
2012 form
United
Healthcare,
nation’s largest
private insurer.

3.7percent of patients with
prediabetes were prescribed
metformin

Academic team
members
analyzed all data
independently
and retained sole
authority over all
publicationrelated decisions
throughout the
study

Obese patients were almost two
times more likely to be
prescribed metformin

All analyses
done using SAS
and STATA.

Women were almost two times
more likely to be prescribed
metformin

Patients with 2 or more
comorbid conditions were 1.5
times more likely to be
prescribed metformin

When patient is taking metformin, early
reduction in glycemia has a stronger
correlation to diabetes risk then weight
loss

Metformin rarely prescribed for diabetes
prevention
Need to understand potential barriers to
safe, tolerable, evidence-based, and costeffective prediabetes therapy
Even with evidence that metformin is
beneficial in prediabetes treatment, it is
still not being translated into practice
Underuse of highly effective prevention
strategy
Lack of translation of a safe, evidencebased therapy for a highly prevalent
condition is problematic
At the very minimum, patients should be
educated regarding the potential benefits
of metformin and ideally offered this
option as prevention
For patient with significant time
commitments and restraints that make
lifestyle changes challenging, metformin
may provide them with prevention
strategies
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The reasons for low metformin use are
not entirely clear, and future studies
should examine an array of patient-,
provider-, and organization-level factors
that may contribute to underuse
Barriers – lack of knowledge about
evidence from providers, “off label” use –
not approved by FDA for prediabetes,
higher priority placed on other medical
needs, reluctance to “medicalize”
prediabetes, lack of awareness of
prediabetes by patients
The evidence for metformin use is
strongest for patients younger than 60
years, those with a BMI greater than 35
kg/m2, or those with a history of
gestational diabetes

Nathan, D. M., Davidson,
M. B., DeFronzo, R. A.,
Heine, R. J., Henry, R. R.,
Pratley, R., & Zinman, B.
(2007). Impaired fasting
glucose and impaired
glucose tolerance:
Implications for care.
Diabetes Care, 30(3),
753–759.

What are IFG and
IGT, and what is their
natural history?

N/A

Expert
Opinion
Level VII

What is known about
the pathogenesis of
IFG and IGT?
How do we define
the natural history of

N/A

Metformin effective although
half as effective as lifestyle
modification, but is inexpensive
and has virtually no long-term
side effects
Acarbose is as effective as
metformin, but many cannot
tolerate its GI side effects and
is costly

Potential strategies to increase awareness
and promote informed decision making
among this at-risk population could
include clinical decision-making tools,
physician directed and performance-based
incentive programs, or media campaigns
to increase public awareness of
prediabetes and its consequences if left
untreated.
Metformin is the safest and cost-effective
anti-diabetic medication as of today,
however, if other medications become
more cost-effective metformin may not be
the best option. With that being said,
metformin has the least amount of side
effects and therefore may always be the
leading anti-diabetic medication based
solely off of side effects
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https://doi.org/10.2337/dc
07-9920

IFG/IGT, and can we
alter it?

Orlistat also has been shown to
be effective but is poorly
tolerated, however, now that it
is an OTC drug, it is less costly

Do interventions that
prevent the
progression from
IFG/IGT to diabetes
also prevent the
development/worseni
ng of diabetes-related
microvascular
complications, cardio
metabolic risk
factors, or CVD
events?

Rosiglitazone was as effective
in dallying/preventing diabetes
as lifestyle modification but is
costly and associated with a
sevenfold increase in heart
failure

Newman, J. D.,
Schwartzbard, A. Z.,
Weintraub, H. S.,
Goldberg, I. J., & Berger,
J. S. (2017). Primary
prevention of
cardiovascular disease in
diabetes mellitus. Journal
of the American College
of Cardiology, 70(7), 883893.

Patients with elevated IFG and IGT and
any of the following: < 60 years of age,
BMI ≥ 35 kg/m2, family history of
diabetes in first-degree relatives, elevated
triglycerides, reduced HDL cholesterol,
hypertension, A1C > 6.0percent should
be treated with lifestyle modifications
and/or metformin
Lifestyle modifications should always be
addressed and used as a foundation;
however, metformin has been proven
effective to help prevent or delay the
progression to T2DM

Are there adequate
data to prevent or
delay diabetes in
IFT/IGT at this time?
Who should be
screening and with
what methods and
frequency to
prevent/delay the
adverse consequence
of IFG/IGT?
Cardiovascular
disease is major risk
factor of T2DM and
most common cause
of death. Need to
expand the use of
therapies proven to
reduce CVD in
diabetic patients

Patients with elevated IFG or IGT with no
other risk factors should be treated
through lifestyle modification (510percent weight loss and moderate
intensity physical activity – 30 min/day

Future recommendations
may include other medications if they
prove to be effective, have a good safety
profile, are tolerable, and are of relatively
low cost.

N/A

Expert
Opinion

N/A

Metformin generally
considered first line therapy for
glycemic control

Level VII
Other pharmacological
strategies such as SGLT2,
GLP-1 analogues have also
shown to reduce vascular risk
Further research is needed to
determine if these agents are
superior or additive in the CVD

CVD risk reduction is critical
Statins, aspirin, glucose-lowering
therapies, and BP reduction should all be
considered along with intensive lifestyle
management
Uniform medical therapies impact
morbidity and mortality of diabetic
patients
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Perreault, L., Kahn,
Steven E., Christophi, C.,
Knowler, W., &
Hamman, R. (2009).
Regression from prediabetes to normal
glucose regulation in the
diabetes prevention
program. Diabetes Care,
32(9), 1583-8.
https://doi.org/10.2337/dc
09-0523

risk reduction with the use of
metformin
Regression from
prediabetes to normal
glucose regulation
was associated with
reduced incidence of
diabetes, examined
whether regression
also reduced risk for
microvascular disease

N/A

Observatio
nal Study

N/A

Level III

For models adjusted for age,
sex, race, ethnicity, baseline
A1C, and treatment odds, a
regression to normal glucose
regulation also lead to a lower
prevalence of microvascular
disease.

Diabetes can be prevented or delayed in
people with prediabetes

When models included average
A1C during follow-up or
diabetes status at the end of
follow-up, the association
between regression to normal
glucose regulation and lower
prevalence of microvascular
disease, no longer existed

Regression to NGR is associated with
lower prevalence of MVD, nephropathy,
and retinopathy

With regression to normal
glucose regulation there was
also a lower prevalence of
nephropathy and retinopathy.
As A1C increased so did MVD,
nephropathy, and retinopathy

Ramachandran A.,
Snehalatha C., Mary S.,
Mukesh B., Bhaskar A.D.,
Vijay V. (2006). The
Indian Diabetes
Prevention Programme
shows that lifestyle
modification and
metformin prevent type 2
diabetes in Asian Indian
subjects with impaired

Progression to
diabetes could be
influenced by
interventions in
native Asian Indians
with IGT who were
younger, leaner, and
more insulin resistant
than multiethnic
Americans, Finnish
and Chinese

n = 531
subjects
(421 men
and 110
women)

Randomize
d Control
Trial
Level II

Group 1 was the
control (n = 136)

Median follow-up period was
30 months

Group 2 given
advice on
lifestyle
modification (n =
133)

3-year cumulative incidences of
diabetes were as follows; group
1 (55.0percent), group 2
(39.3percent), group 3
(40.5percent), and group 4
(39.5percent)

Group 3 was
treated with

Complications can also be prevented in
prediabetics when early intervention is
aimed at reducing body weight, lipids,
blood pressure, and/or plasma glucose

Limiting cumulative glycemic exposure is
central in prediabetes care, whether they
develop diabetes or not
Highlights different relationships between
the microvascular disease subtypes and
glycemia over time
Timing for glucose-lowering
intervention(s) may well need to change
as tools are developed to determine
individual risk for MVD and its subtypes

Can prevent diabetes in native Asian
Indian subjects with IGT using lifestyle
modification
Metformin also effective but in smaller
doses (500 mg/day), which could be
contributed to lower BMI of Asian
Indians
No additional benefit seen by combining
lifestyle modification and metformin
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glucose tolerance (IDPP1). Diabetologia, 49(2),
289–297.
https://doi.org/10.1007/s0
0125-005-0097-z

metformin (n =
133)
Group 4 given
advice on
lifestyle
modification and
prescribed
metformin (n =
129)

Relative risk reduction for
group 2 (28.5percent), group 3
(26.4percent), and group 4
(28.2percent)
Number needed to treat to
prevent one case of diabetes for
group 2 (6.4), group 3 (6.9),
and group 4 (6.5)

Primary outcome
was defined as
development of
T2DM

Rhee, M., Herrick, K.,
Ziemer, D., Vaccarino,
V., Weintraub, W.,
Narayan, K., Kolm, P.,
Twombly, J., & Phillips,
L. (2010). Many
Americans have prediabetes and should be
considered for metformin
therapy. Diabetes Care,
33(1), 49-54.
https://doi.org/10.2337/dc
09-0341

Determine proportion
of Americans who
would merit
metformin treatment,
according to ADA to
prevent or delay
development of
diabetes

n = 4.706
subjects
who
were
nonHispanic
white
and
black,
without
known
diabetes

CrossSectional
Analysis
Level IV

Screening for
Impaired
Glucose
Tolerance
(SIGT)
Third National
Health and
Nutrition
Examination
Survey
(NHANES III)
National Health
and Nutrition
Examination
Survey
(NHANES)

Asian Indians have a very high
progression rate of IGT to diabetes and
therefore are considered high risk based
off ethnicity
LSM was more effective than metformin
in all races, including the ethnic minority
population, and the effect of metformin
was lower in the thinner individuals
Mechanisms responsible for the
beneficial effects of interventions,
independent of weight change, need to be
analyzed

Isolated patients into three
groups, IFG, IGT, and IFG and
IGT. In SIGT, NHANES III,
and NHANES, criteria for
metformin consideration were
met in 99, 96, 96percent with
IFG and IGT, 31, 29, and
28percent with IFT, and 53, 57,
and 62percent with IGT.

It has also demonstrated the effectiveness
that lifestyle modification involving
moderate, but consistent, physical activity
and diet modification help to prevent
diabetes even in the Asian Indians, who
have a high risk of developing diabetes
More than 96percent of individuals with
both IFG and IGT are likely to meet
criteria.
Providers should perform oral glucose
tolerance tests to find concomitant IGT in
all patients with IFG.
Roughly 1/12 adults meet criteria that
may justify consideration of metformin
treatment
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Roberts, S., Barry, E.,
Craig, D., Airoldi, M.,
Bevan, G., & Greenhalgh,
T. (2017). Preventing type
2 diabetes: Systematic
review of studies of costeffectiveness of lifestyle
programmes and
metformin, with and
without screening, for
pre-diabetes. BMJ Open,
7(11), 1-18.
https://doi.org/10.1136/b
mjopen-2017-017184

Explore costeffectiveness of
lifestyle intervention
and metformin, alone
and in combination

27
studies
included
all
evaluated
lifestyle
interventi
ons while
12 also
included
metformi
n

Systematic
Review
Level II
Not all
were RCT

Criteria for
consideration of
metformin
included the
presence of both
impaired
fasting glucose
(IFG) and
impaired glucose
tolerance (IGT),
with ≥1
additional
diabetes risk
factor: age <60
years, BMI ≥
35 kg/m
2, family history
of diabetes,
elevated
triglycerides,
reduced
HDL cholesterol,
hypertension, or
A1C
>6.0percent.
Database
searches
included
Embase,
Medline,
PreMedline, and
NHS EED. The
International
Society for
Pharmacoecomonics and
Outcomes
Research’s
Questionnaire to

Lifestyle programs and
metformin appeared cost
effective, but economic
estimated varied. Intervention
only programs more cost
effective than programs that
included screenings. Longer the
period evaluated, more costeffective.
Insufficient evidence to
determine whether lifestyle
programs are more cost
effective then metformin or

Preventing diabetes is complex and can
be expensive. Although evidence is
insufficient regarding what direction is
most cost-effective, it is important to
consider the advantages and
disadvantages for your patient that is
unique to them. Are you going to be
spending more money in the beginning
(lifestyle interventions and metformin
cost) but ultimately saving cost by
preventing patients delay to T2DM and
complications associated with it.
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Robertson, C. (2012). The
role of the nurse
practitioner in the
diagnosis and early
management of type 2
diabetes. Journal of the
American Academy of
Nurse Practitioners, 24,
225–233.
https://doi.org/10.1111/j.1
745-7599.2012.00719.x

Discuss the state of
knowledge of
effective therapeutic
approaches to
preventing or
dallying T2DM

N/A

Sheng, Z., Cao, J. Y.,
Pang, Y. C., Xu, H. C.,
Chen, J. W., Wang, R.,
Zhang, C. S., Wang, L.
X., & Dong, J. (2019).
Effects of lifestyle
modification and antidiabetic medicine on
prediabetes progress: A
systematic review and
meta-analysis. Frontiers
in Endocrinology,
10(455), 1-15.
https://doi.org/10.3389/fe
ndo.2019.00455

With the
understanding that
pre-diabetes is a risk
factor for T2DM it is
essential to identify
effective preventive
strategies, and to
clarify direction of
future research

32 RCT
comprisi
ng of
43,669
patients
and 14
interventi
ons were
analyzed

Scoping
Review of
Literature

Assess
Relevance and
Credibility of
Modelling
studies for
Informing
Healthcare
Decision Making
– used to assess
study quality.
N/A

whether low-intensity
interventions are more cost
effective then high intensity.

Multifactorial approach is
required to deal with T2DM.
-Lifestyle changes most
important
-Metformin and TZDs –
effective with IGT and higher
BMI

Treatment that is multifactorial and
personalized is most effective. Lifestyle
changes such as increasing exercise or
activity and reducing weight are most
important, but metformin shown to be
effective in patients with IGT and higher
BMI. Pharmacological treatment and
lifestyle interventions together with the
control of cardiovascular risk factors are
main strategies.

PubMed,
Embase, and
Cochrane
Central Register
of Controlled
Trials were
searched

Lifestyle modifications and
anti-diabetic medications
improved physical conditions,
including weight loss, blood
glucose and pressure

There is firm evidence that lifestyle
modifications and metformin reduce
incidence of diabetes with an average
reduction of 20percent

Level IV

Systematic
Review and
MetaAnalysis
Level I

Network metaanalysis applies
to multiple
comparison
among various
diabetic
prevention
strategies,
traditional metaanalysis for

Progression of diabetes can be
delayed to varying degrees by
lifestyle and pharmacological
interventions, except for ACE
Inhibitors, statins,
sulfonylureas, and vitamin D

Lifestyle modifications promising longterm strategies involving nutrition,
exercise, and weight loss contributed to
the following: reduction of BMI, body
weight, waist and hip circumference,
systolic and diastolic pressure, fasting and
2-h postprandial blood glucose, and total
cholesterol
Complications of diabetes increases
patient suffering and mortality
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Souto, S., Souto, E.,
Braga, D., & Medina, J.
(2011). Prevention and
current onset delay
approaches of type 2
diabetes mellitus
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Pharmacology, 67(7),
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Tseng, E., Greer, R.,
O’Rourke, P., Yeh, H.-C.,
McGuire, M., Clark, J., &
Maruthur, N. M. (2017).
Survey of primary care
providers’ knowledge of
screening for, diagnosing
and managing
prediabetes. Journal of
General Internal
Medicine, 32(11), 1172–
1178.
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Discuss the state of
knowledge of
effective therapeutic
approaches to
preventing or
dallying T2DM

N/A

Assess PCPs'
knowledge of risk
factors that should
prompt prediabetes
screening, laboratory
criteria for
diagnosing
prediabetes and
guidelines for
management of
prediabetes;
management
practices around
prediabetes; attitudes
and beliefs about
prediabetes

n = 155
PCPs

Scoping
Review of
Literature

syntheses of
basal metabolic
changes after
interventions,
and trial
sequential
analysis for
determinations
as to whether
analysis
conclusions meet
expectation
N/A

Level IV

Crosssectional
Studies

Descriptive
analyses of
survey questions
conducted.

Level V
Multivariate
logistic
regression used
to determine
association
between provider
characteristics
and knowledge,
management,
and
attitudes/beliefs

Effective interventions early on can
reduce the personal and public health
burden of diabetes
More relevant trials needed to reinforce
or complement review, focusing on
clinical complications and costeffectiveness

Multifactorial approach is
required to deal with T2DM.
-Lifestyle changes most
important
-Metformin and TZDs –
effective with IGT and higher
BMI

Treatment that is multifactorial and
personalized is most effective. Lifestyle
changes such as increasing exercise or
activity and reducing weight are most
important, but metformin shown to be
effective in patients with IGT and higher
BMI. Pharmacological treatment and
lifestyle interventions together with the
control of cardiovascular risk factors are
main strategies.

6percent PCPs correctly
identified all risk factors that
should prompt screening

PCPs need to address gaps in knowledge
regarding prediabetes (risk factors and
diagnostic parameters) and the
underutilization of behavioral weight loss
programs

17percent PCPs correctly
identified laboratory parameters
for diagnosis
90percent PCPs reported close
follow-up
11percent PCPs referred to a
behavioral weight loss program
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about
prediabetes
UK Prospective Diabetes
Study Group. (1998).
Effect of intensive bloodglucose control with
metformin on
complications in
overweight patients with
type 2 diabetes (UKPDS
34). The Lancet,
352(9131), 854-865.
https://doi.org/10.1016/S0
140-6736(98)07037-8

Patients with T2DM,
blood glucose control
decreases progression
of microvascular
disease and risk of
heart attacks.
Investigated whether
intensive glucose
control with
metformin has any
specific advantage or
disadvantage

n = 4,209
patients
from 15
centers

Randomize
d Control
Trial
Level II

4,209 eligible
patients. 2,505
were nonoverweight.
1,704 were
overweight. Of
the 1,704, 411
were assigned
conventional
treatment (diet
alone), 342 were
assigned
intensive control
with metformin,
and 951 were
assigned
intensive control.
Of the 951, 265
were as assigned
chlorpropamide,
277
glibenclamide,
and 409 insulin.
1,234 patients
(overweight and
non-overweight)
assigned to
sulphonylurea.
86 died or no
longer attended
clinics. Of the
1148 patients left
(who had
elevated FPG),
211 not eligible
due to FPG <6.

Patient-related factors are
important barriers to lifestyle
change and metformin use
A1C was 7.4percent in the
metformin group compared to
8.0percent in conventional
group
Patients taking metformin had
risk reduction of 32percent for
any diabetes-related endpoint,
42percent for diabetes-related
death, and 36percent for allcause mortality compared to
conventional group
Metformin showed greater
effect than chlopropamide,
glibenclamide, or insulin for
any diabetes-related endpoint,
all-cause mortality, and stroke
Adding metformin to
sulphonylurea-treated patients
increased risk of diabetesrelated death
Patients taking metformin had
fewer diabetes-related
endpoints

Metformin appears to decrease the risk of
diabetes related endpoints in overweight
diabetic patients
Associated with less weight gain and
fewer hypoglycemic attacks than insulin
and sulphonylureas, and should be
considered first-line pharmacological
therapy for diet-treated overweight
patients
Additional research and studies need to
be conducted on the addition of
metformin in patients already treated with
sulphonylureas
Findings may not apply to nonoverweight patients, but metformin seems
to lower glycaemia in patients, regardless
of obesity status (overweight or not)
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Wang, T., Eguale, T. &
Tamblyn, R. (2013).
Guidelines adherence in
the treatment of patients
with newly diagnosed
type 2 diabetes: A
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Diabetes Association
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Service Research, 13,
442.
https://doi.org/10.1186/14
72-6963-13-442

Measure the response
of PCP who changed
their initial therapy
for patient with
T2DM in relation to
guideline changes

n = 1279
patients
and 111
physician
s

Cohort
Study
Level IV

537 eligible for
randomization
and 411 not
eligible due to
FPG > 15. Of the
537 eligible 269
were on
sulphonylurea
along and 269 on
sulphonylurea
and metformin
EMR Research
Network
Multivariate
GEE logistic
regression was
used to estimate
impact of
guideline change
on treatment
choice

With new guidelines there was
an increased use of metformin
with a decreased use of
thiazolidinediones, and
sulfonylureas.
Physicians attitudes did not
change regarding evidencebased practice

When new guidelines are initiated this
change the practice of prescribing. If
metformin is shown to be effective in
preventing or delaying the progression to
T2DM, the guidelines need to reflect this.

